Re: ‘Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma’

Key Points

• This analysis aims to assess the cost-effectiveness of lisocabtagene maraleucel as a second-line treatment for relapsed large B-cell lymphoma.
• Evaluated the healthcare costs associated with lisocabtagene maraleucel treatment.
• Analyzed potential outcomes against existing second-line therapies.
• Findings indicate significant cost variations when comparing treatments.
• Limitations include the absence of primary data due to no datasets generated.